Having numerous therapies to treat prostate cancer can actually be a bad thing—it makes it difficult to design clinical trials for new therapies coming into the space, explained Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
Having numerous therapies to treat prostate cancer can actually be a bad thing—it makes it difficult to design clinical trials for new therapies coming into the space, explained Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
What are the challenges you see with translating new scientific discoveries into clinical practice?
The biggest challenge in prostate cancer right now is a problem we didn’t have 10 years ago, which is we have too many drug therapies. Well, not that we have too many drug therapies, but it’s hard for new drug therapies to come in and compete for space. So, in fact, if we’re designing a clinical trial, especially a randomized clinical trial, it’s now very difficult to think: what would be the control arm? Both in hormone-sensitive and castration-resistant prostate cancer.
I guess we’re a victim of our own success. We have too many therapies, so a very big challenge now, especially for a new therapy, is [that] to prove overall survival benefit is very, very difficult. And this is why we have to depend on genetic understanding of the patient’s tumors to direct our therapy better. Because the one-size-fits-all therapy, that era is hopefully gone. And a more personalized approach based on the patient’s tumor characteristics and their own mutations will help us, I think, direct treatment more appropriately to the right patients. And that will, in turn, help us to design better and smarter clinical trials.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More